{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T18:42:49Z","timestamp":1740163369258,"version":"3.37.3"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T00:00:00Z","timestamp":1718150400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T00:00:00Z","timestamp":1718150400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s13555-024-01191-3","type":"journal-article","created":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T04:01:53Z","timestamp":1718164913000},"page":"1969-1974","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Successful Treatment of Severe Pemphigus Vulgaris with Reduced Side Effects Using a Novel IVIg Preparation"],"prefix":"10.1007","volume":"14","author":[{"given":"Nadine","family":"Wiedenmayer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anastasia S.","family":"Vollmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia K.","family":"Winkler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1816-421X","authenticated-orcid":false,"given":"Alexander H.","family":"Enk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,6,12]]},"reference":[{"issue":"9","key":"1191_CR1","first-page":"1077","volume":"16","author":"N van Beek","year":"2018","unstructured":"van Beek N, Zillikens D, Schmidt E. Diagnosis of autoimmune bullous diseases. J Dtsch Dermatol Ges. 2018;16(9):1077\u201391.","journal-title":"J Dtsch Dermatol Ges"},{"key":"1191_CR2","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.3389\/fimmu.2019.01974","volume":"10","author":"S Saschenbrecker","year":"2019","unstructured":"Saschenbrecker S, Karl I, Komorowski L, et al. Serological diagnosis of autoimmune bullous skin diseases. Front Immunol. 2019;10:1974.","journal-title":"Front Immunol"},{"issue":"3","key":"1191_CR3","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.jaad.2018.02.021","volume":"82","author":"DF Murrell","year":"2020","unstructured":"Murrell DF, Pe\u00f1a S, Joly P, et al. Diagnosis and management of pemphigus: recommendations of an international panel of experts. J Am Acad Dermatol. 2020;82(3):575\u201385.e1.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"1191_CR4","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1111\/bjd.14463","volume":"174","author":"DY Hsu","year":"2016","unstructured":"Hsu DY, Brieva J, Sinha AA, Langan SM, Silverberg JI. Comorbidities and inpatient mortality for pemphigus in the U.S.A. Br J Dermatol. 2016;174(6):1290\u20138.","journal-title":"Br J Dermatol"},{"issue":"Suppl 1","key":"1191_CR5","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/j.1365-2249.2009.04022.x","volume":"158 Suppl 1","author":"A Durandy","year":"2009","unstructured":"Durandy A, Kaveri SV, Kuijpers TW, et al. Intravenous immunoglobulins\u2013understanding properties and mechanisms. Clin Exp Immunol. 2009;158 Suppl 1(Suppl 1):2\u201313.","journal-title":"Clin Exp Immunol"},{"key":"1191_CR6","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.3389\/fimmu.2019.01090","volume":"10","author":"JHO Hoffmann","year":"2019","unstructured":"Hoffmann JHO, Enk AH. High-dose intravenous immunoglobulin in skin autoimmune disease. Front Immunol. 2019;10:1090.","journal-title":"Front Immunol"},{"issue":"1","key":"1191_CR7","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3390\/biom6010015","volume":"6","author":"AF BarahonaAfonso","year":"2016","unstructured":"BarahonaAfonso AF, Jo\u00e3o CM. The production processes and biological effects of intravenous immunoglobulin. Biomolecules. 2016;6(1):15.","journal-title":"Biomolecules"},{"issue":"5","key":"1191_CR8","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2317762121","volume":"121","author":"AR Ahmed","year":"2024","unstructured":"Ahmed AR, Kalesinskas M, Kaveri SV. Restoring immune tolerance in pemphigus vulgaris. Proc Natl Acad Sci U S A. 2024;121(5):e2317762121.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1191_CR9","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1002\/9781119719809.ch22","volume-title":"Rossi's principles of transfusion medicine","author":"N Brinkman","year":"2022","unstructured":"Brinkman N, McCann K, Gooch B. The purification of plasma proteins for therapeutic use. In: Rossi\u2019s principles of transfusion medicine. Wiley; 2022. p. 216\u201335."},{"issue":"8","key":"1191_CR10","first-page":"810","volume":"18","author":"S Grabbe","year":"2020","unstructured":"Grabbe S, Beissert S, Enk A. Systemic immunosuppression in times of COVID-19: do we need to rethink our standards? J Dtsch Dermatol Ges. 2020;18(8):810\u20133.","journal-title":"J Dtsch Dermatol Ges"},{"issue":"6","key":"1191_CR11","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14265","volume":"33","author":"\u00d6F Elmas","year":"2020","unstructured":"Elmas \u00d6F, Demirba\u015f A, T\u00fcrsen \u00dc, Atasoy M, Lotti T. Pemphigus and COVID-19: critical overview of management with a focus on treatment choice. Dermatol Ther. 2020;33(6): e14265.","journal-title":"Dermatol Ther"},{"key":"1191_CR12","unstructured":"European Medicines Agency. Guideline on core SmPC for human normal immunoglobulin for intravenous administration (IVIg) - Rev. 6 (2021). Reference Number: EMA\/CHMP\/BPWP\/94038\/2007 Rev. 6 Corr. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-core-smpc-human-normal-immunoglobulin-intravenous-administration-ivig-rev-6_en.pdf. Accessed 19 April 2024."},{"issue":"4","key":"1191_CR13","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.jaad.2008.09.052","volume":"60","author":"M Amagai","year":"2009","unstructured":"Amagai M, Ikeda S, Shimizu H, et al. A randomized double-blind trial of intravenous immunoglobulin for pemphigus. J Am Acad Dermatol. 2009;60(4):595\u2013603.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1191_CR14","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.autrev.2015.09.002","volume":"15","author":"P Cherin","year":"2016","unstructured":"Cherin P, Marie I, Michallet M, et al. Management of adverse events in the treatment of patients with immunoglobulin therapy: a review of evidence. Autoimmun Rev. 2016;15(1):71\u201381.","journal-title":"Autoimmun Rev"},{"key":"1191_CR15","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.3389\/fimmu.2018.01299","volume":"9","author":"Y Guo","year":"2018","unstructured":"Guo Y, Tian X, Wang X, Xiao Z. Adverse effects of immunoglobulin therapy. Front Immunol. 2018;9:1299.","journal-title":"Front Immunol"},{"issue":"3","key":"1191_CR16","doi-asserted-by":"publisher","first-page":"206","DOI":"10.2340\/00015555-0249","volume":"87","author":"C Prins","year":"2007","unstructured":"Prins C, Gelfand EW, French LE. Intravenous immunoglobulin: properties, mode of action and practical use in dermatology. Acta Derm Venereol. 2007;87(3):206\u201318.","journal-title":"Acta Derm Venereol"},{"issue":"4","key":"1191_CR17","doi-asserted-by":"publisher","first-page":"211","DOI":"10.2165\/11537660-000000000-00000","volume":"24","author":"P Ch\u00e9rin","year":"2010","unstructured":"Ch\u00e9rin P, Cabane J. Relevant criteria for selecting an intravenous immunoglobulin preparation for clinical use. BioDrugs. 2010;24(4):211\u201323.","journal-title":"BioDrugs"},{"issue":"3","key":"1191_CR18","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s40268-023-00430-w","volume":"23","author":"C Duellberg","year":"2023","unstructured":"Duellberg C, Hannappel A, Kistner S, Maneg O. Biochemical characterization of a new 10% IVIG preparation [IgG next generation (BT595)\/Yimmugo\u00ae] obtained from a manufacturing process preserving IgA\/IgM potential of human plasma. Drugs R D. 2023;23(3):245\u201355.","journal-title":"Drugs R D"},{"issue":"2","key":"1191_CR19","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1111\/tme.12943","volume":"33","author":"J Demeter","year":"2023","unstructured":"Demeter J, Hamed A, L\u00e1szl\u00f3 S, et al. Efficacy and safety of BT595 (10% human intravenous immunoglobulin) in adult patients with chronic immune thrombocytopenia. Transfus Med. 2023;33(2):165\u201373.","journal-title":"Transfus Med"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01191-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-024-01191-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01191-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T17:16:04Z","timestamp":1721495764000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-024-01191-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,12]]},"references-count":19,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["1191"],"URL":"https:\/\/doi.org\/10.1007\/s13555-024-01191-3","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"type":"print","value":"2193-8210"},{"type":"electronic","value":"2190-9172"}],"subject":[],"published":{"date-parts":[[2024,6,12]]},"assertion":[{"value":"2 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Alexander H. Enk received advisory board honoraria, consultancy fees and support for this publication from Biotest AG. Julia K. Winkler received travel expanse and honoraria from Biotest AG. Nadine Wiedenmayer and Anastasia S. Vollmer declare to have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Ethical approval was not required for this case report, in accordance with local and national guidelines.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}